Lupin has received approval from the US health regulator to market Decitabine for Injection, used for the treatment of myelodysplastic syndrome. The company has received approval from the United States Food and Drug Administration to market Decitabine for Injection, 50 mg/vial, single-dose vial, Lupin said in a statement.
Decitabine -- the generic version of Otsuka’s Dacogen for Injection, 50 mg/vial -- had annual sales of approximately $135.9 million in the US. Shares of Lupin were trading at Rs 852.00 apiece on the BSE, up 1.27 per cent, from their previous close.